SEC Stock Data Quick Answer Xtant Medical Holdings, Inc. reported Stockholders Equity of $50.95 million for fiscal year 2025. Xtant Medical Holdings, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $50.95M +18.6% 2024 $42.96M -16.3% 2023 $51.35M +50.3% 2022 $34.17M +10.6% 2021 $30.88M +112.8% 2020 $14.51M +132.8% 2019 -$44.20M -1.0% 2018 -$43.77M +25.4% … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Long-Term Debt of $11.03 million for fiscal year 2025. Xtant Medical Holdings, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $11.03M -50.0% 2024 $22.04M +28.4% 2023 $17.17M +77.2% 2022 $9.69M -17.8% 2021 $11.79M -84.5% 2019 $76.24M -2.2% 2018 $77.94M +16.1% 2017 $67.11M +50.1% … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Cash and Equivalents of $17.05 million for fiscal year 2025. Xtant Medical Holdings, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $17.05M +175.1% 2024 $6.20M +8.5% 2023 $5.71M -71.8% 2022 $20.30M +11.3% 2021 $18.24M +679.3% 2020 $2.34M -55.3% 2019 $5.24M -23.0% … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Total Assets of $94.14 million for fiscal year 2025. Xtant Medical Holdings, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $94.14M +0.3% 2024 $93.84M +1.3% 2023 $92.61M +53.8% 2022 $60.23M +10.1% 2021 $54.69M +31.9% 2020 $41.47M -3.9% 2019 $43.16M -7.0% 2018 $46.42M -56.1% … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Diluted EPS of $0.03 per share for fiscal year 2025. Xtant Medical Holdings, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $0.03 +125.0% 2024 -$0.12 -1300.0% 2023 $0.01 +111.1% 2022 -$0.09 -50.0% 2021 -$0.06 +76.0% 2020 -$0.25 +60.3% 2019 -$0.63 +89.4% 2018 -$5.97 … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Net Income of $4.97 million for fiscal year 2025. Xtant Medical Holdings, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $4.97M +130.2% 2024 -$16.45M -2592.3% 2023 $660.0K +107.8% 2022 -$8.48M -75.0% 2021 -$4.85M +31.0% 2020 -$7.02M +14.6% 2019 -$8.22M +88.3% 2018 -$70.10M -33.7% … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Revenue (ASC 606) of $133.93 million for fiscal year 2025. Xtant Medical Holdings, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $133.93M +14.2% 2024 $117.27M +28.4% 2023 $91.30M +57.5% 2022 $57.97M +4.9% 2021 $55.26M +3.6% 2020 $53.34M -17.5% 2019 $64.68M — … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Total Revenue of $133.93 million for fiscal year 2025. Xtant Medical Holdings, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $133.93M +14.2% 2024 $117.27M +28.4% 2023 $91.30M +57.5% 2022 $57.97M +4.9% 2021 $55.26M +3.6% 2020 $53.34M -17.5% 2019 $64.68M -10.4% 2018 $72.20M -12.6% … Read more
Quick Answer Xtant Medical Holdings, Inc. reported Total Revenue of $133.93 million for fiscal year 2025. Xtant Medical Holdings, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $133.93M+14.2% $117.27M+28.4% $91.30M+57.5% $57.97M+4.9% $55.26M+3.6% $53.34M-17.5% Revenue (ASC 606) $133.93M+14.2% $117.27M+28.4% $91.30M+57.5% $57.97M+4.9% $55.26M+3.6% $53.34M-17.5% Net Income $4.97M+130.2% -$16.45M-2592.3% $660.0K+107.8% -$8.48M-75.0% … Read more
Quick Answer XTL BIOPHARMACEUTICALS LTD reported Gross Profit of $3.0 thousand for fiscal year 2024. XTL BIOPHARMACEUTICALS LTD Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2024 $3.0K — The most recent figure is from XTL BIOPHARMACEUTICALS LTD’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 30, 2025. … Read more